Trial Profile
A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 25 Jan 2023
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Cardiovascular disorders; Kidney disorders; Renal failure
- Focus Registrational; Therapeutic Use
- Acronyms Dapa-CKD
- Sponsors AstraZeneca; AstraZeneca AB; AstraZeneca India; AstraZeneca KK
- 20 Jan 2023 Results of a pre-specified analysis assessing benefits of dapagliflozin in patients with type 2 diabetes and chronic kidney disease published in the Diabetes Care
- 06 Dec 2022 Results of post hoc analysis, evaluating the effects of dapagliflozin on first hospitalizations and all (first and subsequent) hospitalizations and to explore effects on cause-specific hospitalizations, published in the Annals of Internal Medicine
- 01 Dec 2022 Results assessing estimated lifetime survival free of kidney failure in patients with albuminuric CKD without diabetes from two clinical studies: Dapa-CKD and NCT00270426 published in the Clinical Journal of The American Society of Nephrology: CJASN